Pharmaceutical Outsourcing covers news of importance to the contract services segment of the pharmaceutical industry.
Collected from the most trusted on-line resources, these news stories are chosen and published here based on their relevance to the pharmaceutical industry.
Topics of interest typically include: mergers and acquisitions, service additions, new capabilities, personnel changes, news from the FDA and other international regulatory and standard-setting agencies, and new outsourcing contracts and deals.
If you are looking to stay up-to-date with the news in your industry, this resource is vital for your industry knowledge.
Don Kania, Ph.D., has been appointed to the Board of Directors of Aldevron, a global provider of plasmid DNA manufacturing, protein production and antibody discovery services.
read more
Aldevron has announced expansion plans for a 14-acre campus at its headquarters in Fargo, N.D.
read more
Tuesday, December 12, 2017
Aldevron announced a license agreement whereby Aldevron will manufacture and distribute a S. pyogenes Cas9 variant which is patented by IDT.
read more
Aleafia Health’s indirect subsidiary, Emblem Germany GmbH, has formally submitted its application to German regulators for EU Good Manufacturing Practices (EU-GMP) certification.
read more
PCI Synthesis, Inc. (www.pcisynthesis.com), a 12-year-old custom chemical manufacturer of new chemical entities (NCEs), generic active pharmaceutical ingredients (APIs), and other specialty chemical products, today announced that industry veteran ...
read more
Monday, September 21, 2020
Alimera Sciences Europe has signed a distribution agreement with Medis for the exclusive sales and distribution of ILUVIEN in the Czech Republic and Austria.
read more
Tuesday, January 07, 2014
Alkermes plc (NASDAQ:ALKS) today announced that the United States Patent and Trademark Office (USPTO) has issued a Notice of Allowance for U.S. Patent Application 14/032,736, entitled “Prodrugs of fumarates and their use in treating various diseases....
read more
Wednesday, April 17, 2013
Alkermes plc (NASDAQ: ALKS) today announced positive preliminary topline results from a phase 2 study of ALKS 5461, its novel drug compound for major depressive disorder (MDD) in patients who have an inadequate response to standard therapies for ...
read more
Alkermes plc today announced that it has expanded its senior management team by appointing two industry veterans to newly created roles. Srdjan (Serge) Stankovic, M.D., MSPH, will serve as Senior Vice President of Clinical Development and Medical ...
read more
Alkermes plc today will present an overview of its proprietary pipeline portfolio at its Research and Development (R&D) Day meeting for analysts and investors. For the first time, the company will discuss three new drug candidates including: a ...
read more
Saturday, September 25, 2021
Allarity Therapeutics A/S, a clinical-stage precision medicine company actively advancing a pipeline of in-licensed oncology therapeutics for patients with difficult-to-treat cancers, and Lonza, a CDMO partner to the biopharma industry, announced an ...
read more
Thursday, February 23, 2023
AllCells®, a Discovery Life Sciences™ company announced the expansion of its apheresis network with the addition of two new centers in Houston, Texas, and Huntsville, Alabama. These new centers complement AllCells' existing presence in two major U.S....
read more
AGC Biologics announced a new partnership with Allergy Therapeutics, the fully integrated specialty pharmaceutical company specializing in allergy vaccines. The CDMO has manufactured phase I clinical trial materials for Allergy Therapeutics’ novel ...
read more
Allied Patients has launched to develop affordable generic medications and do right by patients.
read more
Following the success of one of its key client partnered products, Craigavon-based pharmaceutical company Almac, has announced the commercial manufacturing expansion. Together with the recent completion of a new non-GMP drug development facility at ...
read more